After five years building and advancing a pharmaceutical pipeline that proved difficult to fund, Christopher Moreau decided it was time to find a new cash flow focused path in healthcare that could provide explosive returns for investors.
The result is Grey Matters Health (CSE:GREY, OTCQB:AGNPD, FRA:AGW0) — a rebranded, refocused company with a singular mission: to build the United States’ first dedicated brain PET scan diagnostic network, starting with a flagship clinic in Florida set to open in September. “When new investors come to the story, they will discover a new, exciting and compelling story says Moreau, the company’s CEO. “This is really a fresh start and a new direction.” The rebrand from Algernon Health reflects both a change in identity and a change in strategy
Drug repurposing, the company’s original focus, is capital-intensive by nature, and access to that capital proved elusive for a CSE-listed firm locked out of US institutional funds because they are unable to buy or invest in CSE listed stocks. Nuclear medicine and neuroimaging, Moreau concluded, offered a more accessible path to building a sustainable, cash-generating healthcare business. Whether he’s right remains to be seen — but the first clinic will offer an early test.
Why brain diagnostics, and why now The move into neuroimaging wasn’t arbitrary. Several converging developments made the sector look compelling. First, the FDA approved two antibody therapies for Alzheimer’s disease targeting amyloid plaque buildup in the brain, but accessing either treatment requires diagnostic confirmation through a brain PET scan or spinal tap.